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Abstract: Evidence about distribution patterns of brain metastases with regard to breast cancer
subtypes and its influence on the prognosis of patients is insufficient. Clinical data, cranial computed
tomography (CT) and magnetic resonance imaging (MRI) scans of 300 breast cancer patients with
brain metastases (BMs) were collected retrospectively in four centers participating in the Brain
Metastases in Breast Cancer Registry (BMBC) in Germany. Patients with positive estrogen (ER),
progesterone (PR), or human epidermal growth factor receptor 2 (HER2) statuses, had a significantly
lower number of BMs at diagnosis. Concerning the treatment mode, HER2-positive patients
treated with trastuzumab before the diagnosis of BMs showed a lower number of intracranial
metastases (p < 0.001). Patients with a HER2-positive tumor-subtype developed cerebellar metastases
more often compared with HER2-negative patients (59.8% vs. 44.5%, p = 0.021), whereas patients
with triple-negative primary tumors had leptomeningeal disease more often (31.4% vs. 18.3%,
p = 0.038). The localization of Brain metastases (BMs) was associated with prognosis: patients with
leptomeningeal disease had shorter survival compared with patients without signs of leptomeningeal
disease (median survival 3 vs. 5 months, p = 0.025). A shorter survival could also be observed in the
patients with metastases in the occipital lobe (median survival 3 vs. 5 months, p = 0.012). Our findings
suggest a different tumor cell homing to different brain regions depending on subtype and treatment.
Int. J. Mol. Sci. 2016, 17, 1615; doi:10.3390/ijms17101615 www.mdpi.com/journal/ijms
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1. Introduction
Brain metastases (BMs) have recently become a major clinical challenge in the management of
patients with metastatic breast cancer. Limited data is available about evidence-based treatment
strategies of this metastatic entity, and little is known about the biology of the disease [1]. Most of the
published data is based on the evaluation of BMs in patient cohorts with different primary tumors,
including patients with lung cancer and malignant melanoma. These results cannot be completely
transferred on breast cancer patients with BMs: the tumor biology as well as modern therapies
distinguish these tumors from other entities.
Several factors for an increased risk of BMs have been identified in breast cancer. Younger patients,
poorly differentiated tumors (high grade) and hormone receptor-negative status have been associated
with increased BM risk. In HER2-positive and TNBC patients with metastatic breast cancer, incidence
rates up to 30%–40% were described [1–3]. Although risk factors that are associated with BM formation
have been identified, little is known about patterns of BMs depending on molecular subtypes or
previous therapies. The biologic characteristics and clinical behavior differ between breast cancer
subtypes. For example, patients with BMs from HER2-positive breast cancer live longer in comparison
to HER2-negative patients [4]. This is probably due to improved treatment options in this group.
Nevertheless, many of these patients develop BMs and the influence of HER2 expression as well as
systemic therapies on tumor cell dissemination into the brain, and the growth of tumor cells within
the particular microenvironment of the brain is barely understood.
The aim of this analysis was therefore to evaluate the patterns of BMs in different breast cancer
subtypes, to estimate an association between BC therapy mode and BM patterns, and to evaluate
survival times with regard to BM patterns. The data can provide a background for the prediction of
the distribution of BMs in breast cancer patients and support further research concerning prevention,
early detection, and treatment of the BMs of breast cancer.
2. Results
2.1. Patients’ Characteristics
300 patients with breast cancer and brain metastases were available for the evaluation. The median
age of the patients at the time of the diagnosis of BMs was 56 years (range: 27–89 years). In 87.3% of
the cases (n = 262), the cerebral metastases were diagnosed with MRI; in 12.7% of patients (n = 38),
they were diagnosed with CT. Median time to the development of BMs from first diagnosis of breast
cancer was 39 months (range: 0–415) and 13 months (range: 0–131) from the first diagnosis of
metastatic disease.
Regarding the number of BMs, 35.0% of the patients (n = 105) had one BM, 15.0% (n = 45) had two
BMs, and 41.0% (n = 123) had three or more BMs. Exactly nine percent of the patients had meningeal
or spinal metastases as the only BM localization. A total of 11.4% of the patients had parenchymal
BMs and leptomeningeal disease simultaneously. Fifty-four percent of primary tumors were hormone
receptor-positive (n = 141), 44% (n = 102) were HER2-positive, and 17% (n = 51) were triple-negative.
A pathological report of brain metastases was available for 135 patients who received surgical resection
of their brain metastases.
During the follow-up period, 58.3% of the patients (n = 175) died. Median survival time after BM
diagnosis was four months (range: 0–91 months). A detailed summary of patients’ characteristics and
therapies is listed in Table 1.
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Table 1. Patients’ characteristics.
Patient’s Characteristic Median or Number Range or Percent
Age at diagnosis of breast cancer in years 51 (median) Range 23–89
Age at diagnosis of BMs in years 56 (median) Range 27–89
Time to brain metastases from first diagnosis of BC in months 39 (median) Range 0–415
Survival after BM diagnosis in months 4 (median) Range 0–91
Estrogen-receptor (n = 261, n = 39 missing data) positive 141 54.0%
negative 120 46.0%
Progesterone-receptor (n = 260, n = 40 missing data) positive 125 48.1%
negative 135 51.9%
HER2-receptor (n = 230, n = 70 missing data) positive 102 44.3%
negative 128 55.7%
Triple-negative primary tumor (n = 281, n = 19 missing data) yes 51 18.1%
no 230 81.9%
Chemotherapy before the diagnosis of BMs (n = 267, missing data n = 33) yes 238 89.1%
no 29 10.9%
Endocrine therapy before the diagnosis of BMs (n = 136, missing data n = 5) yes 116 85.3%
no 20 14.7%
HER2-targeted therapy before the diagnosis of BMs in the subgroup of
patients with a HER2-positive BC (n = 99, missing data n = 3)
yes 85 85.9%
no 14 14.1%
2.2. Brain Metastases Patterns and Tumor Subtype
In our evaluation, we could show that patients with positive estrogen, progesterone, or HER2
statuses of the primary breast cancer tumor had a significantly lower number of BMs, also in specific
brain regions. ER-negative patients had more BMs than ER-positive patients (mean: 15 vs. 7), and this
was also the case for PR-negativity compared with positivity (15 vs. 7) and for HER2-negative
compared with HER2-positive patients (15 vs. 8) (p < 0.001 each, Table 2).
Table 2. Number of the brain metastases depending on BC subtype.
Receptor Status BM Number (Mean, SD) p-Value
Estrogen receptor status positive 7.19 (0.24) <0.001negative 15.26 (0.37)




Regarding patterns of BMs, patients with HER2-positive primary tumors, HER2-positive BMs,
or both had cerebellar metastases more often in comparison with patients with HER2-negative tumors
(59.8% vs. 44.5%, p = 0.021, Figure 1a,b).
A further correlation could be detected between hippocampal metastases (n = 15) and tumor
subtypes. Patients with ER-positive or PR-positive tumor biology, or a combination thereof, had
a lower incidence of hippocampal metastases compared with patients that were ER-negative,
PR-negative, or a combination thereof (2.8% ER-pos. vs. 8.3% ER-neg., p = 0.05; 1.6% PR-pos. vs. 9%
PR-neg., p = 0.009). No significant differences could be detected for patients with HER2-positive or
triple-negative BC.
Leptomeningeal Disease and Tumor Subtype
Patients with triple-negative breast cancer had leptomeningeal involvement more often
(pachymeninx and leptomeninx), diagnosed by imaging (31.4% vs. 18.3%, p = 0.038, Figure 1c).
No significant correlation could be detected for patients with other BC subtypes.
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Figure 1. Association between BM patterns and subtypes: (a) HER2-status of the primary breast 
tumor and cerebellar metastases; (b) HER2-status (brain metastases) and cerebellar metastases; (c) 
Triple-negative BC and leptomeningeal disease. 
2.3. Brain Metastases Patterns and Systemic Therapy 
In our cohort, 44% (n = 102) of patients had HER2-positive primary tumors, and 85.9% (n = 85) 
had received HER2-targeting agents before the diagnosis of BMs: n = 83 trastuzumab, n = 10 
lapatinib, and n = 7 pertuzumab. 
Our analysis indicates that HER2-positive patients treated with trastuzumab before the 
diagnosis of BMs had a lower number of BMs compared with HER2-positive patients without 
previous HER2-targeted therapy (mean 8 vs. 11, p < 0.001). 
Leptomeningeal Disease and Systemic Therapy 
No clinically significant correlation could be detected between the development of 
leptomeningeal disease and the systemic therapy of breast cancer. 
2.4. Brain Metastases Patterns and Patient Outcome 
Median survival time after the diagnosis of BMs was four months (range: 0–91) in our cohort. A 
correlation with survival could be shown for patients with metastases in the occipital lobe: patients 
with occipital lobe metastases (n = 63) had a median survival of three months compared with five 
months for patients without metastases in the occipital lobe (n = 111) (p = 0.012, Figure 2a). 
Figure 1. Association between BM patterns and subtypes: (a) HER2-status of the primary breast
tumor and cerebellar metastases; (b) HER2-status (brain metastases) and cerebellar metastases;
(c) Triple-negative BC and leptomeningeal disease.
2.3. Brain Metastases Patterns and Systemic Therapy
In our cohort, 44% (n = 102) of patients had HER2-positive primary tumors, and 85.9% (n = 85)
had received HER2-targeting agents before the diagnosis of BMs: n = 83 trastuzumab, n = 10 lapatinib,
and n = 7 pertuzumab.
Our analysis indicates that HER2-positive patients treated with trastuzumab before the diagnosis
of BMs had a lower number of BMs compared with HER2-positive patients without previous
HER2-targeted therapy (mean 8 vs. 11, p < 0.001).
Leptomeningeal Disease and Systemic Therapy
No clinically significant correlation could be detected between the development of leptomeningeal
disease and the systemic therapy of breast cancer.
2.4. Brain Metastases Patterns and Patient Outcome
Median survival time after the diagnosis of BMs was four months (range: 0–91) in our cohort.
A correlation with survival could be shown for patients with metastases in the occipital lobe: patients
with occipital lobe metastases (n = 63) had a median survival of three months compared with five
months for patients without metastases in the occipital lobe (n = 111) (p = 0.012, Figure 2a).
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No correlation was detected between other parenchymal BM localizations and survival of
the patients.
Leptomeningeal Disease and Patient Outcome
Patients with leptomeningeal disease (n = 43) had a shorter survival compared with patients
without leptomeningeal disease (n = 130) (median survival 3 vs. 5 months, p = 0.025, Figure 2b).
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This retrospective study of BM patterns in 300 breast cancer patients showed that there may be 
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and the number of BMs. In addition, we give evidence that there may be an association between the 
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Lekanidi et al. evaluated 60 breast cancer patients with BMs and showed that ER-negative 
HER2-positive patients were more likely to present with a larger number of lesions, more brain stem 
or occipital metastases, and hydrocephalus [5]. In our analysis of a large cohort of 300 patients, we 
could confirm that estrogen-negative patients had a higher number of BMs in comparison with 
ER-positive patients. 
Figure 2. Overall survival depending on BM localization (months). (a) Occipital lobe metastases and
survival of the patients; (b) Leptomeningeal disease and survival of the patients.
In multivariate analyses, brain irradiation, neurosurgery, and positive HER2-status of the primary
tumor ere associated with longer survival after the diagnosis of BMs. Age at diagnosis of BMs was
inversely associated with survival: a higher age was associated with an impaired prognosis of patients
(Table 3).
Table 3. Association between patient characteristics and survival (multivariate analysis).
Variable Hazard Ratio p-Value 95% Confidence Interval
HER2-negativity 1.685 0.008 1.144–2. 80
Older age at diagnosis of BMs 1.016 0.037 1.001–1.031
No radiotherapy of the brain 3.297 <0.001 2.042–5.322
No neurosurgery 1.981 0.002 1.297–3.026
3. Discussion
This retrospective study of BM patterns in 300 br ast cancer p tients showed hat ther may be
a link between the histolog c l subtype of the primary tumor, previous therapies and localization,
and the number f BMs. In addition, we give evidence that there may be an association between the
locations of BMs with survival.
To our knowledg , only a few sm ller studies have been published examining the association
between the radiological BM patterns and breast cancer subtype.
Lekanidi et al. evaluated 60 breast cancer patients with BMs and showed that ER-negative
HER2-positive patients were more likely to present with a larger number of lesions, more brain stem
or occipital metastases, and hydrocephalus [5]. In our analysis of a large cohort of 300 patients,
we could confirm that estrogen-negative patients had a higher number of BMs in comparison with
ER-positive patients.
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In line with our results, Niwinska et al. [6] showed that patients with a triple-negative
tumor-subtype had a higher probability to metastasize to the leptomeninges.
We could demonstrate that HER2-positive patients were more likely to metastasize into the
cerebellum, which was also suggested by Tomasevic in a preliminary report on 18 patients [7].
In our cohort of breast cancer patients with BMs, we could show that the number of BMs was also
correlated with previous systemic therapy. The analysis of the correlation between BM patterns and
previous systemic therapy showed that HER2-positive patients treated with trastuzumab before the
diagnosis of BMs had a lower number of BMs in comparison with patients without HER2-targeted
therapy. A protective role of the HER2-targeted therapy concerning the BMs was also suggested by the
findings of Duchnowska et al., where no trastuzumab administration in the metastatic setting was
an independent variable in the development of early BMs [8].
Our finding indicating a lower number of BMs in HER2-positive patients treated with the
HER2-targeting compound trastuzumab could be of clinical relevance since it might be a sign of its
effect in the brain. This has been a controversial issue. Some published data suggests that trastuzumab
only penetrates to a small degree via the blood–brain barrier [9], whereas other investigations indicate
increased trastuzumab levels in cerebrospinal fluid under conditions of an impaired blood–brain
barrier such as BMs [10].
The finding about specific metastases patterns of HER2-positive (cerebellum) and triple-negative
patients (leptomeninges) could have several implications. First, in clinical care, physicians could
pay attention to clinical symptoms associated with each of these metastatic localizations. Moreover,
the different behavior of biologic subtypes, which seems to be also influenced by systemic therapy,
should lead to experimental research that might help to understand the mechanisms underlying such
behavior and finally to improve strategies for the prevention and treatment of BMs.
We initially hypothesized that the temporal lobe and hippocampus were never involved in the
metastatic process to the brain in BC patients, but we could not confirm this hypothesis, as we found
that each region in the brain might be involved in the metastases formation. However, the rate of
hippocampal metastases in our cohort was very low (n = 15 of 300 patients); therefore, radiotherapy
sparing the hippocampal regions to avoid neurologic impairment might be discussed with the patient.
Our findings go with the results of a study by Hong et al., where a low rate of metastases in the
hippocampal region was seen in an analysis of 77 melanoma patients [11].
Concerning the association between BM patterns and prognosis of the patients, several reports
have been published. In our investigation, leptomeningeal disease and occipital lobe metastases were
associated with poor prognosis. Jo et al. and Hyun et al. also described a poor prognosis of patients
with leptomeningeal disease [12,13]. To our knowledge, we are the first to give data about the impact
of other specific BM localizations on the survival of BC patients.
The strength of our analysis is the large sample size of 300 patients with BMs of breast cancer.
However, the evaluation of the scans was done retrospectively, and not all patients had received
an MRI scan of the brain, which does not allow a complete comparison. In addition, only 45% had
received resection of the BMs. We could not take into consideration all cases of possible receptor
changes [14,15] from primary to metastatic sites. The missing information concerning the biological
characteristics of some patients results from a retrospective patient cohort treated several years ago.
However, the inclusion of these patients provided inter alia an opportunity to analyze a historic cohort
of HER2-positive patients without HER2-targeted therapy.
The evaluation of the presented issue in a prospective manner could provide further evidence
about the association of breast cancer subtypes, treatment and radiological BM patterns.
Taken together, we have added new data on the development of BMs depending on tumor
subtype and preceding therapies. The different behaviors of biologic subtypes, which seems to be
additionally dependent on systemic therapy, could lead to research in experimental models that might
help to improve the understanding of mechanisms underlying such behavior and therefore to improve
strategies for the prevention and treatment of BMs.
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4. Materials and Methods
The clinical data of 300 patients with BMs of breast cancer (first diagnosis of breast cancer BMs
between 1986 and 2016) was documented retrospectively and also prospectively in the Brain Metastases
in Breast Cancer (BMBC) Network in Germany [16]. The BMBC registry is approved by the ethics
committee Hessen (processing number FF42/2013). The data for this subanalysis was collected in four
participating German centers: University Medical Center Hamburg-Eppendorf, Hannover Medical
School, the Oncologic Department of the Agaplesion Diakonie-Clinic Rotenburg, and an outpatient
imaging center. The assessment of the cerebral computer tomography (CT) and magnetic resonance
imaging (MRI) at the timepoint of the diagnosis of BMs was performed in all cases with available
image material (n = 271) by one investigator and double-checked in 10% of cases by an independent
investigator. For 29 patients, only the written reports were taken into consideration, as image material
was no longer available. The affected brain regions and the number of the metastases in each brain
area were analyzed. The last follow-up was performed in January 2016.
HER2 positivity was defined as either immunohistochemical staining of 3+ or a positive FISH-result.
The association between the BM localization and the tumor subtype or therapy mode was
calculated with a chi-square test. In cases with surgical resection of BMs and available pathology
reports of the BMs, the association between BM localization, subtype of the primary, and the brain
tumor was analyzed.
Influence of tumor subtype as well as the preceded therapy on the number of BMs was estimated
with Poisson-regression analysis.
Survival analysis was performed with the univariate log-rank test.
The multivariate cox-regression analysis took into consideration the histological subtype of the
primary tumor, the number of BMs, BM treatment, visceral metastases, and the age of BM diagnosis.
Survival was defined as the interval between diagnosis of BMs and the date of death.
Statistical analyses were performed with the SPSS Statistics Software, Version 21 (IBM, SPSS Inc.,
Chicago, IL, USA). Five percent was considered significant.
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